AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Lags Revenue Estimates

AcelRx Pharmaceuticals (ACRX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.16 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 42.86%. A quarter ago, it was expected that this drugmaker would post a loss of $0.15 per share when it actually produced a loss of $0.20, delivering a surprise of -33.33%.
Over the last four quarters…

Click here to view the original article.